7584-11-4

Basic information

• Product Name: 2-Cyano-4,6-dimethylpyridine
• Synonyms: 2-Cyano-4,6-dimethylpyridine
• CAS NO: 7584-11-4
• Molecular Formula: C₈H₈N₂
• Molecular Weight: 132.16252
• Mol File: 7584-11-4.mol
• Article Data: 2

Chemical Properties

• Melting Point: 53-53.5 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 272.179 °C at 760 mmHg
• Flash Point: 102.72 °C
• Appearance: /
• Density: 1.056 g/cm³
• Storage Temp.: 2-8°C
• PKA: 1.06±0.10(Predicted)
• CAS DataBase Reference: 2-Cyano-4,6-dimethylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Cyano-4,6-dimethylpyridine(7584-11-4)
• EPA Substance Registry System: 2-Cyano-4,6-dimethylpyridine(7584-11-4)

Safety Data

• Hazardous Substances Data: 7584-11-4(Hazardous Substances Data)

Usage

Uses

4,?6-?Dimethylpyridine-?2-?carbonitrile is a useful chemical for the preparation of cis-dihydroxylation and epoxidation of olefins with hydrogen peroxide.

Upstream product

• 30838-93-8 2-chloro-4,6-dimethyl-pyridine 
• 1122-45-8 2,4-dimethylpyridine N-oxide 
• 77-78-1 dimethyl sulfate 
• 1118-58-7 1,3-Dimethyl-1,3-butadien 
• 460-19-5 ethanedinitrile 
• 108-47-4 2,4-lutidine 
• 7677-24-9 trimethylsilyl cyanide 

Downstream Products

• 71208-75-8 1-benzyl-2-pyrrolyl 4,6-dimethyl-2-pyridyl ketone 
• 76457-15-3 1-(4,6-dimethylpyridin-2-yl)methanamine 
• 18088-10-3 4,6-dimethylpyridine-2-carboxylic acid 
• 18087-99-5 4,6-dimethyl-2-(hydroxymethyl)pyridine 
• 5439-01-0 4,6-dimethylpyridine-2-carbaldehyde 
• 71208-76-9 2-(1-benzyl-2-pyrrolylmethyl)-4,6-dimethylpyridine 
• 71381-49-2 2-(1-benzyl-2-pyrrolylmethyl)-1,4,6-trimethylpyridinium iodide 
• 79076-68-9 2-(1-benzyl-2-pyrrolidinylmethyl)-4,6-dimethylpyridine 
• 79076-48-5 E-2-<5-(benzylmethylamino)-1-penten-1-yl>-4,6-dimethylpyridine 

Relevant articles and documents

COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS

The present invention relates to compounds as defined herein, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators. In particular, the invention relates to these activator compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3',5-adenosine monophosphate (cAMP).